Market Closed -
London S.E.
11:35:25 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
8
GBX
|
-1.23%
|
|
-1.23%
|
-71.43%
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
198
|
83.07
|
94.41
|
40.96
|
11.54
|
74.85
|
Enterprise Value (EV)
1 |
179.7
|
67.57
|
83.45
|
43.21
|
16.68
|
76.04
|
P/E ratio
|
-96.1
x
|
-29.7
x
|
-21.9
x
|
-6.13
x
|
-1.71
x
|
-5.04
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
167
x
|
91.6
x
|
207
x
|
120
x
|
74.9
x
|
147
x
|
EV / Revenue
|
152
x
|
74.5
x
|
183
x
|
127
x
|
108
x
|
149
x
|
EV / EBITDA
|
-79.1
x
|
-20.1
x
|
-18
x
|
-6.3
x
|
-2.09
x
|
-8
x
|
EV / FCF
|
-77.9
x
|
-32.2
x
|
-30.4
x
|
-6.19
x
|
-4.51
x
|
-16.3
x
|
FCF Yield
|
-1.28%
|
-3.1%
|
-3.29%
|
-16.2%
|
-22.2%
|
-6.13%
|
Price to Book
|
9.88
x
|
4.73
x
|
6.96
x
|
6.14
x
|
4.46
x
|
12.4
x
|
Nbr of stocks (in thousands)
|
92,506
|
92,560
|
92,560
|
92,560
|
100,352
|
202,303
|
Reference price
2 |
2.140
|
0.8975
|
1.020
|
0.4425
|
0.1150
|
0.3700
|
Announcement Date
|
3/14/19
|
1/23/20
|
2/23/21
|
3/1/22
|
3/21/23
|
2/22/24
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.186
|
0.907
|
0.456
|
0.341
|
0.154
|
0.51
|
EBITDA
1 |
-2.271
|
-3.359
|
-4.63
|
-6.862
|
-7.995
|
-9.51
|
EBIT
1 |
-2.602
|
-3.723
|
-4.951
|
-7.512
|
-8.601
|
-10.17
|
Operating Margin
|
-219.39%
|
-410.47%
|
-1,085.75%
|
-2,202.93%
|
-5,585.06%
|
-1,993.73%
|
Earnings before Tax (EBT)
1 |
-2.423
|
-3.386
|
-4.91
|
-7.629
|
-7.567
|
-11.41
|
Net income
1 |
-1.953
|
-2.8
|
-4.313
|
-6.682
|
-6.71
|
-10.83
|
Net margin
|
-164.67%
|
-308.71%
|
-945.83%
|
-1,959.53%
|
-4,357.14%
|
-2,122.75%
|
EPS
2 |
-0.0223
|
-0.0303
|
-0.0466
|
-0.0722
|
-0.0673
|
-0.0734
|
Free Cash Flow
1 |
-2.306
|
-2.096
|
-2.742
|
-6.979
|
-3.7
|
-4.658
|
FCF margin
|
-194.46%
|
-231.08%
|
-601.37%
|
-2,046.7%
|
-2,402.92%
|
-913.36%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/19
|
1/23/20
|
2/23/21
|
3/1/22
|
3/21/23
|
2/22/24
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
2.25
|
5.14
|
1.19
|
Net Cash position
1 |
18.3
|
15.5
|
11
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.3277
x
|
-0.6425
x
|
-0.125
x
|
Free Cash Flow
1 |
-2.31
|
-2.1
|
-2.74
|
-6.98
|
-3.7
|
-4.66
|
ROE (net income / shareholders' equity)
|
-12.3%
|
-14.9%
|
-27.7%
|
-67.3%
|
-145%
|
-251%
|
ROA (Net income/ Total Assets)
|
-9.67%
|
-11.7%
|
-18.1%
|
-31%
|
-40.2%
|
-46.3%
|
Assets
1 |
20.19
|
23.91
|
23.8
|
21.57
|
16.68
|
23.4
|
Book Value Per Share
2 |
0.2200
|
0.1900
|
0.1500
|
0.0700
|
0.0300
|
0.0300
|
Cash Flow per Share
2 |
0.2000
|
0.0600
|
0.0700
|
0.0200
|
0.0100
|
0.0300
|
Capex
1 |
0.44
|
0.4
|
0.11
|
2.69
|
0.36
|
0.25
|
Capex / Sales
|
37.02%
|
44.1%
|
23.46%
|
789.74%
|
235.71%
|
49.02%
|
Announcement Date
|
3/14/19
|
1/23/20
|
2/23/21
|
3/1/22
|
3/21/23
|
2/22/24
|
|
1st Jan change
|
Capi.
|
---|
| -71.43% | 20.31M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|